UNSPSC 51372601: Diampromide

This classification denotes an opioid receptor agonist with the molecular formula C21H28N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 26G7YC77BU, chemically known as propionanilide, n-(2-(methylphenethylamino)propyl)- but generally known as diampromide, which bears US NIH Compound Identifier 62370. European Medicines Agency schedules Diampromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07065MIG.

UNSPSC 51372601 Diampromide is a Commodity code that nominally identifies a specific pharmaceutical substance, but recent state and local solicitations under this code show minimal direct purchasing activity for diampromide itself. Instead, the opportunities tagged to this code reflect broader pharmaceutical procurement spanning naloxone, generic multi-source pharmaceuticals, and over-the-counter products, suggesting the code may be applied by some jurisdictions as a catch-all pharmaceutical or controlled-substance tag rather than for the named active ingredient alone. State and local buyers using this code include county health departments, state health and human services agencies, and cooperative purchasing alliances spanning multiple states. Seminole County, Florida has solicited naloxone and drug deactivation systems through competitive bidding; the Texas Health and Human Services Commission has issued a request for information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) has solicited generic pharmaceuticals and OTC products from manufacturers for distribution through authorized wholesalers serving state and local government facilities across multiple states including Oregon.

Geographic activity clusters in Florida, Texas, and Minnesota, with the Minnesota cooperative purchasing vehicle spanning a multistate footprint. The Seminole County IFB (IFB60459723LAS) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. The Minnesota MMCAP RFP (S1070000015802) for generic multi-source pharmaceuticals and OTC products required proposals by March 26, 2026, with awarded products effective July 1, 2026, and evaluated vendors on pricing competitiveness (75 percent weight), fixed pricing and compliance (20 percent combined), and EDI capability (5 percent). The Texas HHS RFI (HHS0017013) posted April 3, 2026, gathered preliminary market intelligence on direct-to-manufacturer prescription programs to inform future formal procurement strategy. Vendors pursuing this code should treat it as a signal of pharmaceutical and health-supply commodity procurement rather than a reliable indicator of diampromide-specific demand.